A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy - Abstract

Oregon Health and Science University Knight Cancer Institute, Portland, Oregon.

Login to read more...

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use Privacy Policy | © 2010 UroToday ® All Rights Reserved